Tilray | TRLY - Loan Capital


Tilray reported $268.59M in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
Acasti Pharma USD 0 0 Dec/2024
Akebia Therapeutics USD 36.39M 11.85M Mar/2026
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Aurora Cannabis CAD 33.2M 1.79M Dec/2025
Avita Medical AUD 42.24M 1.25M Dec/2024
Canopy Growth CAD 224.99M 1.34M Dec/2025
Dianthus Therapeutics USD 0 0 Dec/2024
Divis Laboratories Ltd INR 50M 30M Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
IQVIA Holdings USD 13.99B 105M Mar/2026
Knight Therapeutics CAD 57.78M 26.92M Dec/2025
Moderna USD 603M 7M Mar/2026
Organigram Holdings CAD 62.52M 13.88M Dec/2025
Organon & Co USD 8.55B 75M Mar/2026
Revvity USD 2.63B 836K Mar/2026
Tectonic Therapeutic USD 43K 57K Dec/2025
Tilray USD 268.59M 3.82M Sep/2025
Viatris USD 12.41B 67.1M Mar/2026
Xeris Pharmaceuticals USD 221.22M 889K Mar/2026
Zealand Pharma A/S 383.14M 727K Dec/2025